Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*-Reference-Cited by-同舟云学术

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*

Published:2012-06 Issue:6 Volume:18 Page:1042-1047
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Fiorino Gionata,Peyrin-Biroulet Laurent,Naccarato Patrizia,Szabò Hajnalka,Sociale Orsola R.,Vetrano Stefania,Fries Walter,Montanelli Alessandro,Repici Alessandro,Malesci Alberto,Danese Silvio

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference27 articles.

1. Etiopathogenesis of inflammatory bowel diseases

2. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

3. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

4. Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024;Expert Review of Vaccines;2024-09-11

2. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation;Journal of the American Academy of Dermatology;2024-06

3. Prevalence Rates of Pneumococcal Vaccination in IBD and 30-Day Clinical Outcomes in Patients With IBD and Pneumococcal Disease Stratified by Receipt of Pneumococcal Vaccination: A Multi-Network Study;Crohn's & Colitis 360;2023-10-01

4. Adherence to Recommended Immunization Schedules in Patients with Inflammatory Bowel Disease on Biologics and Small Molecule Therapies;Gastroenterology Insights;2023-09-14

5. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease;Vaccine;2023-06